PastIn Person

Pharma and Biotech Patent Litigation Conference

by Kisaco Research

The Pharma and Biotech Patent Litigation Conference is a premier European forum dedicated to life sciences intellectual property (IP) professionals. Organized by Kisaco Research, this event is scheduled to take place from January 19 to 21, 2026, at the Beurs van Berlage in Amsterdam, Netherlands. It serves as a platform for IP counsel and litigators to benchmark enforcement strategies, navigate evolving Unified Patent Court (UPC) case law, and prepare for upcoming biosimilar and generic challenges.

The conference agenda focuses on critical issues defining market exclusivity and driving litigation across Europe. Key topics include preliminary injunctions, UPC procedures and case law, Supplementary Protection Certificates (SPCs), Bolar exemptions, second medical use claims, and biosimilar launch strategies. The program aims to equip attendees with the knowledge to defend exclusivity, manage parallel litigation across jurisdictions, and adapt to the unified enforcement landscape emerging under the UPC.

Attendees can expect a structured 1-2-1 meeting program, shared networking spaces, and curated receptions, facilitating targeted meetings with key clients, prospects, or peers. This format ensures that law firms, service providers, and corporate legal teams maximize the value of their attendance through meaningful, business-driven interactions. The event also features sessions with UPC judges, regulatory experts, and litigation funders who will share practical insights on new procedural and evidentiary frameworks shaping outcomes across Europe.

This conference is ideal for life sciences companies, including pharmaceutical innovators, biotechs, generics, and biosimilar developers, as well as private practice litigators. Attendees will benefit from benchmarking litigation strategies, learning directly from UPC decision-makers, exchanging insights with industry peers, and preparing for future regulatory and market developments that directly impact exclusivity and portfolio value.

Speakers(10)

Clemens Heusch

Head of Global Disputes and Resolution at Nokia

Clemens Heusch leads Nokia's global dispute resolution efforts as the Head of Global Disputes and Resolution.

Corinna Sundermann

Senior Vice President Intellectual Property at Fresenius Kabi

Corinna Sundermann serves as the Senior Vice President of Intellectual Property at Fresenius Kabi, leading the company's IP initiatives.

Gabriele Mohsler

Vice President Patent Development at Ericsson

Gabriele Mohsler is the Vice President of Patent Development at Ericsson, overseeing the company's patent portfolio.

Georg Müller

Head of IP at TomTom

Georg Müller is the Head of Intellectual Property at TomTom, managing the company's IP assets.

Ief Daems

Senior Legal Counsel at Cisco

Ief Daems is a Senior Legal Counsel at Cisco, specializing in intellectual property law.

James Horgan

Chief IP Counsel - Policy and Litigation at MSD

James Horgan is the Chief IP Counsel for Policy and Litigation at MSD, managing the company's intellectual property policies and legal disputes.

Julia Pike

Global Head of IP at Sandoz

Julia Pike is the Global Head of Intellectual Property at Sandoz, overseeing the company's IP strategy and litigation.

Le Chen

Senior Legal Counsel at Xiaomi

Le Chen serves as Senior Legal Counsel at Xiaomi, focusing on intellectual property matters.

Ronny Thomas

UPC Local Division Judge

Ronny Thomas is a judge at the Unified Patent Court's Local Division, contributing to the development of European patent law.

Wolfram Thomas

Senior Legal Counsel at Qualcomm

Wolfram Thomas serves as Senior Legal Counsel at Qualcomm, focusing on patent litigation and strategy.

Event Details

Date
January 19-21, 2026
3 days
Location
🇳🇱 Amsterdam, Netherlands
Beurs van Berlage
Pricing
Free Registration
Audience
Life sciences IP professionals, including pharmaceutical innovators, biotechs, generics, biosimilar developers, and private practice litigators.
Attendees
Approximately 600 attendees, with a 45% in-house counsel ratio.